iPremom’s latest research has been published in Nature Communications, presenting a major advance in the early prediction of preeclampsia. The study demonstrates that maternal plasma cell-free RNA (cfRNA) can accurately identify women at risk of developing both early- and late-onset preeclampsia weeks before clinical symptoms appear.
Conducted across 14 Spanish hospitals and involving more than 9,500 pregnancies, this prospective study revealed cfRNA signatures capable of predicting early-onset preeclampsia up to 18 weeks before diagnosis (AUC = 0.88) and late-onset cases up to 15 weeks in advance (AUC = 0.90).
These findings support the clinical application of iPremom’s MaiRa Test, a non-invasive blood test designed to anticipate pregnancy complications from the first trimester, representing an important step toward safer and more personalized prenatal care.
Read the full article in Nature Communications
